Back to top

Image: Bigstock

Medivation, Inc.

Read MoreHide Full Article

Medivation’s first quarter results were disappointing with the company missing on the top- as well as bottom-line. Xtandi sales in the U.S. were affected by several factors including gross-to-net adjustments. However, the sequential decline in Xtandi sales was expected. Going forward, Xtandi sales should pick up with increased usage among urologists. The company is evaluating Xtandi in several studies and is looking to expand its label further. We are also positive on the company’s efforts to build an immuno-oncology franchise. Meanwhile, we remain concerned about the company’s dependence on Xtandi for growth. Moreover, competition in the prostate cancer market is intense.

Published in